Pharma Roundup: Pfizer, Wyeth, Amgen, Bristol, and More

Pfizer and Wyeth: how many jobs are actually being cut? -- The Health Blog provides a run-down on the various figures that are being tossed around, from 18,000 to 26,000. Their estimate (with the math to back it up) is 19,425 from the combined company, with at least 8,190 coming from Pfizer alone. [Source: WSJ Health Blog]

In merger, desperate biotech companies lose a lifeline -- M&A speculation has been running high recently, and many industry insiders expected Pfizer to poach a number of biotechs -- biotechs with promising pipelines but no cash of their own. Now that Pfizer's money is tied up in the Wyeth deal, biotechs have seen one of their potential white knights ride away. [Source: FierceBiotech]

Amgen and Bristol-Myers Squibb in relatively strong financial shape -- It's earnings call season, and both BMS and Amgen turned in year-over-year profit increases. [Source: FiercePharma]